UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdiction of incorporation or organization) 215 First Street, Suite 415 Cambridge, MA 02142 (Address of principal executive offices) (Zip Cod ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bank of America Securities 2021 Napa BioPharma Virtual Conference June 16, 2021 10:30 AM ET Company Participants Doug Ingram - President and CEO Ian Estepan Stan - CFO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Tazeen Ahmad Okay. Good morning, everybody. Thanks for joining us at the Bank of America Virtual Napa Conference. It's my pleasure this morning to have with us Sarepta as our next presenting company. For the next 50 minutes, I ha ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Goldman Sachs 42nd Annual Global Healthcare Conference Call June 10, 2021 1:20 PM ET Company Participants Douglas Ingram - President and Chief Executive Officer Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc. Salveen Richter Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. Thanks for joining us. We are really pleased to have Sarepta with u ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) RBC Capital Markets Global Healthcare Conference May 18, 2021 2:30 PM ET Company Participants Ian Estepan - EVP & CFO Douglas Ingram - President, CEO & Director Conference Call Participants Brian Abrahams - RBC Capital Markets Q - Brian Abrahams Hi, good afternoon everyone. I'm Brian Abrahams, Senior Biotech Analyst at RBC Capital Markets. I'm really pleased to have with us our next presenting company, Sarepta Therapeutics, represented by their CFO, Ian Estepan. Ian, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2021 Earnings Conference Call May 5, 2021 5:30 PM ET Company Participants Mary Jenkins - IR Douglas Ingram - President, CEO & Director Ian Estepan - EVP & CFO Dallan Murray - SVP & Chief Commercial Officer Gilmore O'Neill - EVP, R&D and Chief Medical Officer Louise Rodino-Klapac - EVP & Chief Scientific Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Gil Blum - Needham & Company Colin Bristow - UBS Daniil Gataulin - Raymond James ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Cowen 41st Annual Health Care Conference March 3, 2021 2:40 PM ET Company Participants Doug Ingram - Chief Executive Officer Conference Call Participants Ritu Baral - Cowen and Company Ritu Baral Hey, everyone. Thanks for joining us at the Sarepta fireside chat at the Cowen 2021 Health Care Conference. Hopefully, our first and only virtual health care conference for Cowen. With us from Sarepta, we have CEO, Doug Ingram; CFO, Ian Estepan; and CMO, Gilmore O'Neill, who ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2020 Earnings Conference Call March 1, 2021 4:30 AM ET Corporate Participants Mary Jenkins - Senior Manager, Investor Relations 2Doug Ingram - President and Chief Executive Officer Ian Estepan - SVP, Chief of Staff and Corporate Affairs Gilmore O’Neill - EVP, R&D and Chief Medical Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Office Conference Call Participants Alethia Young - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Salve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Our mission continues. KAI Living with Duchenne muscular dystrophy J.P. MORGAN HEALTHCARE CONFERENCE – JANUARY 2021 ©SAREPTA THERAPEUTICS, INC. 2021. ALL RIGHTS RESERVED. 1 Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease. At Sarepta, every day is another twenty-four hours to stand up for patients, advance technology, challenge convention, and drag tomorrow into today. DOUGLAS INGRAM President and Chief Executive Officer JP Mor ...